Please ensure Javascript is enabled for purposes of website accessibility

Why Immunomedics' Stock Spiked Today

By George Budwell - Sep 8, 2015 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive clinical-update for its lead antibody-drug conjugate sent Immunomedics' shares higher today.

What: Shares of Immunomedics (IMMU), a small-cap antibody-based therapeutics company developing treatments for cancer and autoimmune diseases, briefly rose by as much as 21% today on heavy volume. The stock's rapid rise was triggered by a positive clinical update for the company's lead antibody-drug conjugate (ADC), sacituzumab govitecan, in a midstage study for relapsed or refractory metastatic lung cancer. 

Per the press release, an interim analysis based on 57 patients, that included 28 non-small-cell lung cancer (NSCLC) and 29 small-cell lung cancer (SCLC) patients, suggested that the drug was exhibiting a noteworthy therapeutic signal in a heavily pre-treated group of patients.

Digging into the details, Immunomedics said that about a third of both NSCLC and SCLC patients receiving doses less than or equal to 12 mg/kg exhibited objective responses. The small groups of NSCLC and SCLC patients receiving the 10 mg/kg dose were also showing an interesting trend in terms of median progression-free (PFS) survival as well. The company plans on adding more patients to this dosage cohort going forward to further assess PFS and overall survival. 

So what: Immunomedics' shares took a beating earlier this year after its licensing partner UCB announced that epratuzumab failed to meet its primary endpoint in a late-stage study for lupus. This failure put the onus squarely on 90Y-Clivatuzumab tetraxetan, as a potential treatment for pancreatic cancer, to create value to shareholders in the near-term. With sacituzumab govitecan now showing some compelling midstage results in the metastatic lung cancer arena, Immunomedics' pipeline once again has a couple of interesting clinical candidates that could drive shares higher in the short to intermediate future.

Now what: Immunomedics is plotting a broad development program for sacituzumab govitecan across a host of indications such as NSCLC and SCLC, as well as triple-negative breast, esophageal, urothelial, and colorectal cancers, according to the company. Unfortunately, the drugmaker exited the second quarter of 2015 with only $99.6 million in cash, cash equivalents, and marketable securities, meaning that a major expansion in its clinical activities will probably require a sizable secondary offering. As such, you may want to stick to the sidelines with this speculative biotech until its long-term financing needs are secure. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunomedics, Inc. Stock Quote
Immunomedics, Inc.
IMMU

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.